Delayed 18F-FDG PET/CT in Improving Visualization of Brain Tumors in Patients With Glioblastoma

Improved Visualization of Glioblastoma Using Delayed 18F-FDG PET/CT.

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02919332

Enrollment

Registered

2016-09-29

Start date

2016-06-08

Completion date

2018-12-12

Last updated

2020-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma, Glioma

Brief summary

This clinical trial studies how well delayed fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET)/computed tomography (CT) works in improving visualization of brain tumors in patients with glioblastoma. Radiotracers such as 18F-FDG are highly taken up by tumors in the brain and are visualized using PET/CT. Increasing the interval of time between 18F-FDG administration and PET/CT scan may improve the visualization of brain tumors in patients with glioblastoma.

Detailed description

PRIMARY OBJECTIVES: I. To improve the visualization/delineation of glioblastoma lesions using delayed 18F-FDG PET/CT imaging. OUTLINE: Patients receive fludeoxyglucose F-18 intravenously (IV). Patients then undergo a standard of care PET/CT scan at 60 minutes and a second PET/CT scan at 240 minutes after injection. Note: Standard Uptake Value (SUV) is defined for state-of-the art PET/CT scanners as Standardized uptake values = count activity per ml within region of interest (MBq/ml)/\[injected dose (MBq)/body weight (kgx1000)\]

Interventions

PROCEDUREComputed Tomography

Undergo 18F-FDG PET/CT

RADIATIONFludeoxyglucose F-18

Given IV

PROCEDUREPositron Emission Tomography

Undergo 18F-FDG PET/CT

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

* Patients with histologically proven high grade glioma scheduled for 18F-FDG PET/CT

Exclusion criteria

* Severe psychiatric illness * Inability to give written consent * Breast feeding/pregnancy

Design outcomes

Primary

Measure	Time frame	Description
Tumor-to-background ratio on delayed scans (240 min after injection)	Baseline up to 240 minutes after injection	Ratio between Standardized uptake values (tumor region) and Standardized uptake values (physiological uptake of brain tissue)
Tumor-to-background ratio on standard scans (60 min after injection)	Baseline up to 60 minutes after injection	Ratio between Standardized uptake values (tumor region) and Standardized uptake values (physiological uptake of brain tissue)

Secondary

Measure	Time frame	Description
Standard uptake value comparison	240 minutes post injection	Comparison of Standardized uptake values (tumor region) to visual and quantitative parameters on delayed scans (240 min after injection)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026